AbCellera price target lowered to $12 from $20 at Benchmark

Benchmark lowered the firm’s price target on AbCellera to $12 from $20 and keeps a Buy rating on the shares after the company reported Q2 results. Management did not provide detailed financial guidance going forward, notes the firm, which cites reduced valuations for other drug discovery stocks for its lower AbCellera target.